Results 101 to 110 of about 5,257 (166)

Effects of low-dose tolvaptan on electrolyte abnormality and hemodynamic parameters in a liver cirrhosis-associated portopulmonary hypertension patient: A case report

, 2016
Yoshito Ogihara, Norikazu Yamada, Kaoru Dohi, Akimasa Matsuda, Satoshi Ota, Ken Ishikura, Mashio Nakamura, Masaaki Ito   +7 more
openalex   +2 more sources

Urinary Exosomal Aquaporin-2 Expression and the Efficacy of Tolvaptan in Advanced CKD Patients with Congestive Heart Failure: An Interim Report [PDF]

, 2018
Kenzo Kodaka, Emiko Kuribayashi Okuma, Shigeyuki Arai, Michito Nagura, Yoshifuru Tamura, Shigeru Shibata, Yoshihide Fujigaki, Shunya Uchida   +7 more
openalex   +1 more source

Aquaporin-2 in the early stages of the adenine-induced chronic kidney disease model. [PDF]

PLoS One
Oronel LH, Ortiz M, Yarza C, Gayone S, Davio C, Majowicz M, Albertoni Borghese MF.   +6 more
europepmc   +1 more source

P904Early commencement of tolvaptan therapy improves clinical outcomes in heart failure patients with preserved function of renal vasopressin V2 receptors [PDF]

, 2018
T Noto, Masaya Tanno, Nobutaka Nagano, Arata Osanami, Hidemichi Kouzu, Nobuaki Kokubu, Toshiyuki Yano, Takayuki Miki, Tetsuji Miura   +8 more
openalex   +1 more source

Syndrome of inappropriate antidiuretic hormone secretion following extensively drug-resistant <i>Klebsiella pneumoniae</i> associated with complicated urinary tract infection: a case report. [PDF]

Front Med (Lausanne)
Li J, Yang Z, Wang K, Zha B, Du Y, Shi J, Jie Z, Ding H.   +7 more
europepmc   +1 more source

Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities. [PDF]

Toxicol Sci
Hammond S, Meng X, Barber J, Mosedale M, Chadwick A, Watkins PB, Naisbitt DJ.   +6 more
europepmc   +1 more source

Safety and Efficacy of Long-Term Use of Tolvaptan in Patients With Heart Failure and Chronic Kidney Disease

, 2017
Yusuke Uemura, Rei Shibata, Kenji Takemoto, Tomohiro Uchikawa, Masayoshi Koyasu, Shinji Ishikawa, Ryo Imai, Yuta Ozaki, Takashi Watanabe, Tsubasa Teraoka, Masato Watarai, Toyoaki Murohara   +11 more
openalex   +2 more sources

Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial. [PDF]

Clin Exp Nephrol
Higashihara E, Matsukawa M, Jiang H.
europepmc   +1 more source

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database. [PDF]

Front Pharmacol
Cao P, Wang Q, Wang Y, Qiao Q, Yan L.
europepmc   +1 more source

Spot Versus 24-Hour Urine Osmolality Measurement in Autosomal Dominant Polycystic Kidney Disease: A Diagnostic Test Study. [PDF]

Kidney Med
Akbari A, Sriperumbuduri S, Mangalgi S, Joshi V, Sood M, Buh A, Biyani M, McCudden C, Hundemer GL, Brown PA.   +9 more
europepmc   +1 more source